Table 1 Characteristics and summary of results for the studies of immunotherapy of metastatic castration-resistant prostate cancer included in the network meta-analysis
Trial | Experimental arm | Control arm | OS | PFS | ORR | Jadad’s score | |||
|---|---|---|---|---|---|---|---|---|---|
HR | 95%CI | HR | 95%CI | n/tot | n/tot | ||||
NCT00861614 (CA184-043) | Ipilimumab | Placebo | 0.83 | 0.71–0.96 | 0.7 | 0.61–0.82 | 211/393 | 133/396 | 3 |
NCT01057810 (CA184-095) | Ipilimumab | Placebo | 1.11 | 0.88–1.39 | 0.67 | 0.55–0.80 | 202/399 | 43/199 | 3 |
NCT01133704 (D9902A) | Sipuleucel-T | APC-Placebo | 0.79 | 0.48–1.28 | 0.92 | 0.59–1.45 | 3 | ||
NCT00065442 (D9902B) | Sipuleucel-T | APC-Placebo | 0.78 | 0.61–0.98 | 0.95 | 0.77–1.17 | 3 | ||
NCT00005947 (D9901) | Sipuleucel-T | Placebo | 0.59 | 0.39–0.88 | 0.69 | 0.47–1.01 | 3 | ||
NCT02111577 (SP005) | DCVAC/PCa With Standard of Care Chemotherapy | Placebo With Standard of Care Chemotherapy | 1.042 | 0.90–1.21 | 1.08 | 0.91–1.28 | 3 | ||
NCT01322490 (BNIT-PRV-301) | PROSTVAC-V/F-TRICOM + GM-CSF Placebo | Placebo Control | 1.01 | 0.84–1.20 | 3 | ||||